Correlative Findings from a Multi-agent, Multi-center Trial in CLL

Relapse/ refractory CLL cases were enrolled on a clinical trial at five centers around the United States, with an aim to assess the effect of a combination of a novel Btk inhibitor, Ibrutinib and known therapeutic agents, on their clinical performance. Therapy-induced changes in immune cell populations and circulating chemokine levels were assessed. The findings discussed here indicate significant changes in the immune profiles in a large proportion of the cases and reflect the efficacy of the combination of therapeutic agents under study.

Video Comments

Log in to post a comment about this video.

Video Options

    • Add to Bookmarks